Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ingevity Corporation (NYSE: NGVT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered context to help interpret them. Ingevity is a specialty materials and chemical manufacturer organized into three segments—Performance Materials, Advanced Polymer Technologies and Performance Chemicals—and its filings document how these businesses are managed, restructured and financed over time.
Investors can use Ingevity’s Form 10-K annual reports and Form 10-Q quarterly reports to review segment information, including sales and EBITDA for Performance Materials (activated carbon), Advanced Polymer Technologies (caprolactone polymers) and Performance Chemicals (specialty chemicals and pavement or road technologies). These reports also describe the applications for Ingevity’s products, such as adhesives, agrochemicals, asphalt paving, certified biodegradable bioplastics, coatings, elastomers, pavement markings, lubricants, oil drilling and automotive components.
Ingevity’s Form 8-K current reports are particularly important for tracking material events that affect NGVT stock. Recent 8-K filings detail the asset purchase agreement and subsequent amendment with Mainstream Pine Products, LLC for the sale of the North Charleston crude tall oil refinery and the majority of the Industrial Specialties product line, the classification of those operations as discontinued, and the completion of the transaction. Other 8-Ks describe leadership transitions in finance and business segments, the completion of a portfolio review and the decision to explore strategic alternatives for the Advanced Polymer Technologies segment and the Performance Chemicals Road Markings business, as well as preliminary earnings announcements.
On this page, AI-generated summaries highlight the key points of each filing, helping users quickly understand what a lengthy 8-K, 10-Q or 10-K means for Ingevity’s portfolio, margins, cash flow and capital allocation. Filings related to stock repurchases, strategic divestitures and executive changes are surfaced so that investors can monitor how the company is reshaping its specialty chemicals and materials portfolio. Users can also review exhibits referenced in 8-Ks, such as asset purchase agreements and recast financial information, to gain deeper insight into the structure and impact of major transactions.
Ingevity Corp director Francis David Segal received a grant of 329 vested deferred stock units at $72.28 per unit. These units were issued in lieu of quarterly director fees and increase his directly owned common stock-related position to 6,380 shares.
The deferred stock units will convert into an equal number of Ingevity common shares when his board service ends, under the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Ingevity Corp director J. Kevin Willis reported an equity award of 398 shares of Common Stock on Form 4. The award reflects vested deferred stock units elected in lieu of quarterly director fees at an implied price of $72.28 per share. Following this grant, Willis directly holds 9,177 shares. These deferred stock units will convert into an equal number of Ingevity common shares when his board service ends under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Ingevity Corporation entered into a Second Amendment and Restatement Agreement that modifies its main credit facility. The amendment extends the maturity of the company’s revolving credit facility to a date five years after March 26, 2026 and reduces total lender commitments from $1 billion to $750 million.
Borrowings will bear interest at either a term benchmark rate, with a 0.00% floor, plus a margin of 1.00% to 1.75%, or a base rate plus a margin of 0.00% to 0.75%. On the closing date, Ingevity repaid outstanding revolving loans totaling $512.1 million.
Ingevity Corp senior executive handles RSU tax obligations through share withholding. SVP, General Counsel & Secretary Ryan C. Fisher had 308 shares of common stock withheld by the company at a price of $71.78 per share to satisfy tax liabilities from 2024 RSUs that vested. After this tax-withholding disposition, he directly holds 18,194 common shares.
The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting no beneficial ownership of Ingevity Corp common stock. The filing states 0 shares and 0% ownership after an internal realignment that disaggregated certain subsidiaries' holdings in reliance on SEC Release No. 34-39538. The signature block shows Ashley Grim, Head of Global Fund Administration.
Ingevity Corporation’s 2026 proxy statement presents a transformed “New Ingevity” focused on two core specialty materials businesses: Performance Materials and Pavement Technologies. In 2025 the company completed a strategic portfolio review, agreed to sell its Industrial Specialties business and North Charleston crude tall oil refinery for $110 million and closed the divestiture on January 1, 2026.
For 2025, Ingevity reported $1.29 billion in revenue, a total adjusted EBITDA of $397.5 million and a total adjusted EBITDA margin of 30.8%, alongside a net loss of $(167.1) million. Free cash flow was $273.5 million and the net debt ratio improved to 2.6x, supported by six consecutive quarters of margin expansion.
The company returned $56 million to stockholders through share repurchases in 2025 and plans to generate approximately $1 billion in deployable cash over the next two years, including at least $300 million in additional repurchases, while funding organic growth and debt reduction. Stockholders are asked to elect nine directors, approve say‑on‑pay, ratify PwC as auditor, and increase authorized shares under the 2025 Omnibus Incentive Plan.
Ingevity Corp senior vice president of operations Clarence Reid Clontz Jr. reported equity compensation changes. He acquired 2,343 shares of common stock on a grant or award basis at $0.00 per share, tied to restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan that will vest in three equal installments on February 27, 2027, 2028, and 2029. He also had several small tax-withholding dispositions on March 2, 2026, where 143, 264, 49, and 270 shares of common stock were withheld by the company at $71.64 per share to satisfy tax obligations related to 2023, 2024, and 2025 RSUs that vested. Following these transactions, his directly owned common stock holdings were reported in the 9,000–9,700 share range after each step.
Ingevity Corp senior vice president of finance and chief accounting officer Phillip John Platt reported a mix of equity grants and tax-related share dispositions. On February 27, 2026, he acquired 2,108 restricted stock units under the 2025 Omnibus Incentive Plan, vesting in three equal installments on February 27, 2027, 2028, and 2029. On March 2, 2026, the company withheld a total of 1,070 common shares at $71.64 per share to cover tax obligations tied to vested RSUs from 2023, 2024, and 2025, reducing his directly owned common stock to 29,949 shares.
Ingevity Corp executive Ryan C. Fisher, SVP, General Counsel & Secretary, reported equity compensation activity and related tax withholding. On February 27, 2026, he acquired 4,442 shares of common stock at $0.00 per share as a grant of restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan, scheduled to vest in three equal installments on February 27, 2027, February 27, 2028, and February 27, 2029. On March 2, 2026, a total of 1,333 shares of common stock were disposed of in four transactions coded as tax-withholding dispositions at $71.64 per share, with footnotes stating the shares were withheld by the company to satisfy tax withholding obligations related to vested RSUs from 2023, 2024, and 2025. Following these transactions, Fisher directly owned 18,502 shares of Ingevity common stock.